Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

WIN 2019 Symposium /
Direct targeting of STAT3 alone and in combination with immune checkpoint inhibitors to treat solid tumours

23rd - 24th Jun 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 10.07.19
Views: 255
Rating:

Dr David Tweardy - The University of Texas MD Anderson Cancer Center, Houston, USA

Dr David Tweardy speaks to ecancer at the WIN 2019 Symposium in Paris about a drug program targeting STAT3, a cancer molecule involved in most cancers.

He explains that they began looking at STAT3 25 years ago as it was discovered to be a major master regulator within the cell after coming into contact with interleukin 6, a hormone that circulates upon any injury or illness.

If an injury persists and STAT3 continues to be activated then this can cause cancer.

Dr Tweardy explains that this is why molecules were developed to try and 'turn it off' and that now this is the process of trying to convert this finding into drugs.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation